Analysts say those taking exposure through stocks could look at firms focused on domestic business
Investment in market leaders with a safety-first approach could yield reasonable returns across sectors.
Analysts are eyeing bigger launches that will positively impact company's fortunes.
In the Sensex pack, ICICI Bank emerged as the top gainer by rising 0.97 per cent, while Tata Steel advanced 0.92 per cent.
Dr Reddy's shrugged off recent volatility on Wednesday and moved tenaciously on filing new gernerics with the US FDA.
Kapiva's plans to introduce allopathy-like doses of ayurvedic remedies for the millennial consumer finds traction.
A widening probe by US authorities involving top drug companies following complaints of price fixing of generics was a point of worry for the participants, said analysts.
The broader markets ended negatively with mid-caps and small-caps shedding 0.5 per cent on the BSE.
Its Waluj manufacturing facility in Maharashtra failed to meet the good manufacturing norms prescribed by the UK drug regulator.
Financials were the top losers while oil shares also declined amid weak crude oil prices.
The company did not comply to the 'good manufacturing practice' norms.
The procedure, however, would cost around Rs 75,000-100,000 more than conventional angioplasty.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
'Nothing in this world is permanent. So also in business.' 'And more so in family businesses where family issues often influence business decisions,' point out S Subramanian and Nupur Pavan Bang.
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
Pharma major Ranbaxy Laboratories has set aside Rs 257.4 crore (Rs 2.57 billion) towards the financial impact of a US ban on import of products made at its plant at Toansa.
.jpg)
Markets ended flat on Tuesday, amid a volatile trading session, as investors exercised caution ahead of the two-day FOMC meet starting today and Reserve Bank of India's monetary policy later this week.
IT, pharma and FMCG stocks are the top performers in 2013.
According to Munjal, there is an opportunity for somebody who comes from a not for profit background in health care to do something.
The combined sales of the branded versions of the products in the US is about $3.5 billion.
An International Policy Network report in 2010 found that seven per cent of drugs bought from wholesale traders were substandard, and 3.6 per cent of the drugs from traders contained no active ingredient whatsoever.
Nestle now has less than two weeks to convince the regulator why product approval for its noodles should not be withdrawn
Sun Pharma profit down 30% over compliance costs, lower sales.
With global markets pushing ahead, enthused by strengthening US jobs market, and also due to prospects of European rate hike, Indian markets also continued the march ahead.
Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D.
Rate sensitive sectors were among the top gainers with Tata Motors and ICICI Bank leading the gains on the Sensex.
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
'India easily remains one among the more attractive large economies, with high growth and stable/improving macros, as a top investment destination.' 'We are looking pretty good.'
The S&P BSE Sensex closed 318 points at 24,455 and the Nifty50 shed 99 points to end at 7,438.
Sun Pharma's offer was tempting because Ranbaxy was too busy fighting fires in the US to concentrate on operations.
Indian equity markets registered their highest single-day percentage gains since early October.
Another year of strong performance by these export-oriented sectors likely as US economy revives and rupee is expected to be under pressure.
Lack of clarity on whether manufacturing bans in Punjab, Uttarakhand, Himachal, Goa and Karnataka still in place
Gujarat has around 3,000 licensees for allopathic drug manufacturing, apart from around seven homeopathic licensees, 500 ayuvedic and 600-700 cosmetics licensees
Sensex, Nifty put up a good show in closing trade.
The past eight months have seen vast improvement in the Indian economy, says Edelweiss Group chairman and chief executive Rashesh Shah, who feels domestic-oriented sectors are likely to do better.
Market breadth is positive with 942 advances and 196 declines.
The S&P BSE Sensex closed at 26,190, up by 43 points and Nifty50 settled above 7,950 to end at 7,963, up by 17 points
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
Aneesh Phadnis and Veena Mani find out what the manufacturers and the hospitals have to say.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances